Published in AIDS Weekly, August 9th, 1999
The findings was discussed by the study's principal investigator, Robert Belshe, MD, Saint Louis University, at the International Society for Sexually Transmitted Diseases Research Meeting, held in Denver, Colorado, during July 1999.
This is the second Phase II HIV vaccine trial, and the largest to date, sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The trial, known as AVEG 202/HIVNET 014, is being carried out at 14 sites...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.